2 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
| 1 | 35285277 | Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial. | 2022 May | 1 |
| 2 | 31739184 | Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. | 2020 Jan | 1 |